DrugCite
Search

VIGAMOX

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Vigamox Adverse Events Reported to the FDA Over Time

How are Vigamox adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Vigamox, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Vigamox is flagged as the suspect drug causing the adverse event.

Most Common Vigamox Adverse Events Reported to the FDA

What are the most common Vigamox adverse events reported to the FDA?

Toxic Anterior Segment Syndrome
115 (11.02%)
Endophthalmitis
48 (4.6%)
Eye Pain
44 (4.21%)
Off Label Use
40 (3.83%)
Visual Acuity Reduced
40 (3.83%)
Eye Irritation
25 (2.39%)
Corneal Oedema
18 (1.72%)
Medication Error
18 (1.72%)
Post Procedural Complication
17 (1.63%)
Drug Ineffective
16 (1.53%)
Vitritis
14 (1.34%)
Show More Show More
Retinal Detachment
11 (1.05%)
Ocular Hyperaemia
10 (.96%)
Vision Blurred
10 (.96%)
Conjunctival Hyperaemia
9 (.86%)
Blindness Unilateral
8 (.77%)
Condition Aggravated
8 (.77%)
Erythema Of Eyelid
8 (.77%)
Eye Pruritus
8 (.77%)
Eye Swelling
8 (.77%)
Keratitis Fungal
8 (.77%)
Nausea
8 (.77%)
Ulcerative Keratitis
8 (.77%)
Complications Of Transplant Surgery
7 (.67%)
Erythema
7 (.67%)
Headache
7 (.67%)
Hypersensitivity
7 (.67%)
Hypopyon
7 (.67%)
Iridocyclitis
7 (.67%)
Photophobia
7 (.67%)
Poor Quality Drug Administered
7 (.67%)
Anaphylactic Shock
6 (.57%)
Corneal Disorder
6 (.57%)
Dizziness
6 (.57%)
Drug Hypersensitivity
6 (.57%)
Eye Discharge
6 (.57%)
Eyelid Oedema
6 (.57%)
Hypotony Of Eye
6 (.57%)
Intraocular Pressure Increased
6 (.57%)
Keratitis
6 (.57%)
Lacrimation Increased
6 (.57%)
Loss Of Consciousness
6 (.57%)
Pruritus
6 (.57%)
Corneal Erosion
5 (.48%)
Corneal Opacity
5 (.48%)
Corneal Transplant
5 (.48%)
Dyspnoea
5 (.48%)
Heart Rate Increased
5 (.48%)
Pain In Extremity
5 (.48%)
Pyrexia
5 (.48%)
Treatment Noncompliance
5 (.48%)
Anterior Chamber Fibrin
4 (.38%)
Blindness
4 (.38%)
Blood Pressure Increased
4 (.38%)
Corneal Abrasion
4 (.38%)
Corneal Perforation
4 (.38%)
Diplopia
4 (.38%)
Eye Haemorrhage
4 (.38%)
Eye Infection Bacterial
4 (.38%)
Lenticular Opacities
4 (.38%)
Musculoskeletal Stiffness
4 (.38%)
Palpitations
4 (.38%)
Procedural Complication
4 (.38%)
Rash
4 (.38%)
Swelling Face
4 (.38%)
Urticaria
4 (.38%)
Arthralgia
3 (.29%)
Bacterial Infection
3 (.29%)
Blood Pressure Decreased
3 (.29%)
Corneal Infiltrates
3 (.29%)
Disease Progression
3 (.29%)
Dysphagia
3 (.29%)
Epistaxis
3 (.29%)
Eye Infection
3 (.29%)
Eye Infection Fungal
3 (.29%)
Eye Infection Staphylococcal
3 (.29%)
Eyelid Ptosis
3 (.29%)
Fatigue
3 (.29%)
Hypoaesthesia Facial
3 (.29%)
Hypoaesthesia Oral
3 (.29%)
Hypotonia
3 (.29%)
Impaired Healing
3 (.29%)
Joint Swelling
3 (.29%)
Oedema Peripheral
3 (.29%)
Pain
3 (.29%)
Post Procedural Infection
3 (.29%)
Product Quality Issue
3 (.29%)
Scleral Disorder
3 (.29%)
Staphylococcal Infection
3 (.29%)
Tendon Pain
3 (.29%)
Vitreous Disorder
3 (.29%)
Vomiting
3 (.29%)
Wheezing
3 (.29%)
Wrong Technique In Drug Usage Proce...
3 (.29%)
Acanthamoeba Infection
2 (.19%)
Anterior Chamber Disorder
2 (.19%)
Application Site Irritation
2 (.19%)
Atrial Fibrillation
2 (.19%)
Atrophy Of Globe
2 (.19%)
Bacterial Culture Positive
2 (.19%)
Blister
2 (.19%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Vigamox, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Vigamox is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Vigamox

What are the most common Vigamox adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Vigamox, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Vigamox is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Vigamox According to Those Reporting Adverse Events

Why are people taking Vigamox, according to those reporting adverse events to the FDA?

Cataract Operation
65
Drug Use For Unknown Indication
48
Postoperative Care
47
Product Used For Unknown Indication
42
Prophylaxis
37
Intraocular Lens Implant
21
Show More Show More
Antibiotic Prophylaxis
15
Preoperative Care
13
Conjunctivitis Infective
11
Keratitis
10
Endophthalmitis
9
Conjunctivitis
9
Conjunctivitis Bacterial
8
Ulcerative Keratitis
8
Eye Infection
7
Eye Discharge
5
Antibiotic Therapy
3
Infection Prophylaxis
3
Suture Removal
3
Eye Disorder
3
Corneal Abrasion
3
Photorefractive Keratectomy
3
Cataract
3
Keratitis Fungal
3
Eye Operation
2
Scleritis
2
Dry Eye
2
Infection
2
Conjunctival Abrasion
1
Ophthalmologic Treatment
1
Hordeolum
1
Conjunctivitis Allergic
1
Keratitis Bacterial
1
Eye Inflammation
1
Herpes Zoster
1
Retinal Vein Occlusion
1
Corneal Operation
1
Corneal Ulcer
1
Eye Injury
1
Corneal Lesion
1
Corneal Infiltrates
1
Mydriasis
1
Corrective Lens User
1
Cataract Operation Complication
1

Drug Labels

LabelLabelerEffective
Vigamox Alcon Laboratories, Inc.31-JUL-11
VigamoxRebel Distributors Corp13-SEP-11
Vigamox Physicians Total Care, Inc.07-NOV-11

Vigamox Case Reports

What Vigamox safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Vigamox. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Vigamox.